- A large UK study found statin use in adults with type 2 diabetes was linked to fewer deaths and fewer major heart events across all predicted heart risk levels.
- People classed as low risk still appeared to benefit, challenging the idea that statins are only worthwhile for those at highest short term risk.
- Side effects were uncommon in the data, but the right choice depends on your overall health, other medicines and a shared decision with your clinician.
Statins are medicines that lower LDL cholesterol, often called bad cholesterol.
Lowering LDL reduces the build up of fatty deposits in arteries and can cut the risk of heart attacks and strokes.
Because type 2 diabetes raises the risk of cardiovascular disease over time, statins are commonly used as part of prevention.
In this new analysis, researchers reviewed UK health records for adults aged 25 to 84 with type 2 diabetes who had no previous major cardiovascular disease at the start of follow up.
They compared people who started statins with similar people who did not and tracked outcomes for up to 10 years.
The key result was consistency.
Statin use was associated with lower rates of death from any cause and fewer major cardiovascular events across every baseline risk group, including those whose predicted 10 year cardiovascular risk was considered low.
On safety, the study reported very few problems.
- Continuous glucose monitoring in gestational diabetes may lower the risk of a large baby
- Cardiovascular events among people with type 2 diabetes reduced by quick use of statins
- “Alarming numbe” of people refusing the medication
There was a small increase in muscle related side effects in one subgroup, but no clear signal of increased liver related harm, which is a common concern for many people considering statins.
What this means in practice is simple: short term risk scores may not fully capture who stands to gain from preventive treatment in type 2 diabetes.
If you have diabetes and are unsure whether a statin is right for you, it is worth discussing your longer term risk, your blood results and your preferences with your GP or diabetes team rather than relying on a single risk estimate.
